Rashtriya Newsflash

DelveInsight’s “Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Cancer Anorexia Market Report

https://www.delveinsight.com/report-store/cancer-anorexia-market

Some of the key facts of the Cancer Anorexia Market Report:

• The cancer anorexia market size was valued at around USD 500 million in 2025 and is anticipated to witness significant growth during the forecast period from 2026 to 2036.

• In November 2025, Artelo Biosciences provided business highlights. The interim Phase II Cancer Appetite Recovery Study (CAReS) results demonstrated meaningful efficacy, safety, and functional benefit in cancer-related anorexia and weight loss. Patients receiving top-dose ART27.13 achieved an average +6.4% weight gain.

• In September 2025, Encouraging interim findings from the Phase 2 Cancer Appetite Recovery Study (CAReS), a pivotal trial assessing the investigational cannabinoid receptor agonist ART27.13 for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS), indicate that the therapy could represent a promising new treatment approach for this condition, which affects up to 80% of patients with cancer and currently lacks FDA-approved therapies. The CAReS trial (EudraCT-2022-000464-27) is a Phase 1/2 randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of ART27.13 in patients with CACS.

• Among the 7MM, the US accounted for the highest number of incident cases of cancer anorexia with ~285,600 cases in 2025.

• Among EU4 and the UK, Germany accounted for the highest number of incident cases of cancer anorexia, while Spain accounted for the fewest incident cases.

• Among all cancer types, lung cancer accounts for the highest incidence of cancer anorexia in the US.

• In 2025, the incident cases of pancreatic cancer were ~67,440, and incident cases of lung cancer were ~226,650 in the US.

• According tosecondary analysis, an estimated 72,680 people in the US will be diagnosed with cancer of the oral cavity, pharynx, or larynx, which are the major types of HNC in 2025.

• As per studies, nearly 153,000 new cases of CRC in 2025, with men expected to represent a slightly higher number of cases than women.

• Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others

• Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others

• The Cancer Anorexia epidemiology based on gender analyzed that Cancer Anorexia occurs in both men and women

• The Cancer Anorexia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Anorexia pipeline products will significantly revolutionize the Cancer Anorexia market dynamics.

Cancer Anorexia Overview

The cancer anorexia-cachexia syndrome (CACS), which includes anorexia, is a common sign of cancer.Reduced intake is caused by a lack of appetite or a loss of desire to eat, however this alone cannot explain the complex changes that characterize the CACS.

To Know in detail about the Cancer Anorexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Anorexia Market Forecast

Cancer Anorexia Epidemiology

The Cancer Anorexia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Anorexia Epidemiology Segmentation:

The Cancer Anorexia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Selected Indications

• Total Incident Cases Cancer Anorexia

• Treated Cases of Cancer Anorexia

Download the report to understand which factors are driving Cancer Anorexia epidemiology trends @ Cancer Anorexia Epidemiology Forecast

Cancer Anorexia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Anorexia market or expected to get launched during the study period. The analysis covers Cancer Anorexia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Anorexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Anorexia Therapies and Key Companies

• ADLUMIZ/EDOLMIZU: Helsinn Healthcare

• Adlumiz: Helsinn Healthcare

• ART27.13: Artelo Biosciences

• NGM120: NGM Biopharmaceuticals

Discover more about therapies set to grab major Cancer Anorexia market share @ Cancer Anorexia Treatment Market

Cancer Anorexia Market Drivers

• Rising Global Cancer Burden: The increasing prevalence of various cancers worldwide is significantly driving the incidence of cancer-related anorexia and cachexia conditions.

• Growing Awareness of Supportive Cancer Care: Increasing focus on improving quality of life and nutritional management in oncology care is supporting the demand for cancer anorexia therapies.

• Advancements in Therapeutic Development: Ongoing research into appetite stimulants, anti-inflammatory agents, hormonal therapies, and targeted treatments is expanding the therapeutic landscape.

• Increasing Geriatric Population: The aging population, which is more vulnerable to cancer and associated complications such as anorexia, is contributing to market growth.

Cancer Anorexia Market Barriers

• Limited Approved Treatment Options: The market currently has a limited number of approved therapies specifically targeting cancer anorexia, restricting treatment availability.

• Complex Disease Mechanism: Cancer anorexia is influenced by multiple metabolic, inflammatory, and psychological factors, making treatment development challenging.

• Difficulty in Early Diagnosis: Symptoms of cancer anorexia are often underrecognized or overlap with other cancer-related complications, leading to delayed diagnosis and treatment.

• High Clinical Trial Failure Rates: Challenges in demonstrating consistent efficacy and safety outcomes may hinder the development and approval of new therapies.

Scope of the Cancer Anorexia Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others

• Key Cancer Anorexia Therapies: ADLUMIZ/EDOLMIZU, Adlumiz, ART27.13, NGM120, and others

• Cancer Anorexia Therapeutic Assessment: Cancer Anorexia current marketed and Cancer Anorexia emerging therapies

• Cancer Anorexia Market Dynamics: Cancer Anorexia market drivers and Cancer Anorexia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cancer Anorexia Unmet Needs, KOL’s views, Analyst’s views, Cancer Anorexia Market Access and Reimbursement

To know more about Cancer Anorexia companies working in the treatment market, visit @ Cancer Anorexia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cancer Anorexia Market Report Introduction

2. Executive Summary for Cancer Anorexia

3. SWOT analysis of Cancer Anorexia

4. Cancer Anorexia Patient Share (%) Overview at a Glance

5. Cancer Anorexia Market Overview at a Glance

6. Cancer Anorexia Disease Background and Overview

7. Cancer Anorexia Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Anorexia

9. Cancer Anorexia Current Treatment and Medical Practices

10. Cancer Anorexia Unmet Needs

11. Cancer Anorexia Emerging Therapies

12. Cancer Anorexia Market Outlook

13. Country-Wise Cancer Anorexia Market Analysis (2022–2036)

14. Cancer Anorexia Market Access and Reimbursement of Therapies

15. Cancer Anorexia Market Drivers

16. Cancer Anorexia Market Barriers

17. Cancer Anorexia Appendix

18. Cancer Anorexia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/